Cite
HARVARD Citation
Delea, T. et al. (2019). Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. Journal of medical economics. pp. 117-130. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Delea, T. et al. (2019). Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. Journal of medical economics. pp. 117-130. [Online].